RealTime Dynamix: Psoriasis US Q2 2017 Spotlight

While AbbVie’s Humira and Amgen’s Enbrel have borne the brunt of the IL-17 assault, Janssen’s Stelara has been buffered thus far. However, future projections indicate a flattening of the brand and further penetration of the IL-17 class. Just published RealTime Dynamix: Psoriasis Q2 2017 from Spherix Global Insights provides key insights on the shifting PsO market.

Click the button below to view highlights from the cardiology and nephrology perspective reports:

Download Report Spotlight

2017-10-17T19:51:32+00:00